APRICUS BIOSCIENCES, INC [APRI] TO RING THE NASDAQ STOCK MARKET CLOSING BELL
ADVISORY, March 8, 2012 (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc [APRI], a San Diego based, revenue-generating specialty pharmaceutical company, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Dr. Bassam Damaj, Chairman, President and Chief Executive Officer, will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Friday, March 9th, 2012 – 3:45 p.m. to 4:00 p.m. ET
Public Affairs Director, Washington, D.C.
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at: http://www.facebook.com/#!/NASDAQ.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx
A live webcast of the NASDAQ Closing Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com.
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Apricus Biosciences, Inc [APRI]:
Apricus Bio is a San Diego-based revenue-generating specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT® technology.
Apricus Bio currently markets Totect® (dexrazoxane HCl), the only drug approved in the US for the treatment of anthracycline extravasation. The Company also plans to market in 2012 in the U.S. or certain other countries the following products: (a) Granisol® (granisetron HCI) oral solution, the only FDA-approved, oral, ready-to-use liquid solution of granisetron, (b) Aquoral™, an FDA-cleared, prescription-only spray for the treatment of Xerostomia (the medical term for dry mouth due to a lack of saliva) and (c) NitroMist® (nitroglycerin sublingual spray), an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease (narrowing of the blood vessels that supply blood to the heart).
Apricus Bio's current NexACT® pipeline includes Vitaros® , approved in Canada for the treatment of erectile dysfunction, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.
The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiary please visit http://www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com.
*Please follow NASDAQ OMX on Facebook (http://www.facebook.com/#!/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx).